SELLAS Life Sciences Group, Inc. SLS
Set alert
8.81 USD +0.26 +3.04%
As of Nov 3, 1:56 PM ET
8.57 Day range 9.18
1.39 52-week range 15.88
- YTD
- +133.69%
- 1 year
- +392.18%
- Open
- 8.70
- Prev close
- 8.55
- Mkt cap
- 1.78B
- Vol
- 3.29M
- Avg vol
- 6.79M
- EPS
- -0.21
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 8.57
- High
- 9.18
- Forward P/E
- -85.50
- Beta
- 2.70
- Short ratio
- 10.31
- Inst. own
- 37.00%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 18, 2026
- 50-d avg
- 12.16
- 200-d avg
- 8.57
- 1y target
- 32.50
6M chart
Events in this range
- May 12, 2026Earnings: -0.05; estimate -0.06; surprise 16.67%
- Aug 11, 2026Earnings: -0.05; estimate -0.045; surprise -11.11%
Signals (27)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 29, 2026 | 5 days ago |
| SMA: Bearish | Oct 28, 2026 | 6 days ago |
| SMA: Bullish | Oct 27, 2026 | 1 week ago |
| SMA: Bearish | Oct 22, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 21, 2026 | 1 week ago |
| SMA: Bullish | Oct 20, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 16, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 15, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 9, 2026 | 3 weeks ago |
| MACD: Buy Signal | Oct 9, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 7, 2026 | 3 weeks ago |
| SMA: Bearish | Sep 11, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 1, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 13, 2026 | 2 months ago |
| SMA: Bullish | Aug 3, 2026 | 3 months ago |
| SMA: Bearish | Jul 28, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 13, 2026 | 3 months ago |
| RSI: Overbought | Jul 2, 2026 | 4 months ago |
| RSI: Overbought | Jun 25, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 24, 2026 | 4 months ago |
Newest 20 of 27.
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 32.50 +268.9% upside
Now 8.81
- Target (low)
- 30.00
- Target (mean)
- 32.50
- Target (high)
- 35.00
Ratings (0m) 2 2 buy · 0 hold · 0 sell
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 2
- 1 month ago 2
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.05 | -0.05 – -0.05 | -0.06 | +16.7% | 0 | 0.0% | 1 |
| Next quarter | -0.05 | -0.05 – -0.05 | -0.05 | 0.0% | 0 | 0.0% | 1 |
| Current year | -0.20 | -0.20 – -0.20 | -0.25 | +20.0% | 0 | 0.0% | 1 |
| Next year | -0.10 | -0.20 – 0.00 | -0.20 | +50.0% | 53.09M | 0.0% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 12, 2026 | Maxim Group | Maintained | Buy | Buy |
| Jul 16, 2025 | Maxim Group | Maintained | Buy | Buy |
| Nov 22, 2023 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Sep 7, 2023 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Nov 15, 2022 | Alliance Global Partners | Maintained | — | Buy |
| Jun 28, 2022 | Cantor Fitzgerald | Maintained | — | Overweight |
| Jul 21, 2021 | Cantor Fitzgerald | Initiated | — | Overweight |
| Nov 15, 2019 | Maxim Group | Upgrade | Hold | Buy |
| Apr 8, 2019 | Alliance Global Partners | Initiated | — | Buy |
| Nov 1, 2018 | Oppenheimer | Initiated | — | Outperform |
| Jul 20, 2018 | Maxim Group | Maintained | Buy | Buy |
| Apr 2, 2018 | HC Wainwright & Co. | Initiated | — | Buy |
| Mar 19, 2018 | Maxim Group | Upgrade | Hold | Buy |